Alzheimer's Disease News and Research

RSS

Alzheimer's disease (AD) is an irreversible, progressive brain disease that slowly destroys memory and thinking skills and, eventually, the ability to carry out the simplest tasks of daily living. In most people with AD, symptoms first appear after age 60. AD is the most common cause of dementia among older people, but it is not a normal part of aging. Dementia refers to a decline in cognitive function that interferes with daily life and activities. AD starts in a region of the brain that affects recent memory, then gradually spreads to other parts of the brain. Although treatment can slow the progression of AD and help manage its symptoms in some people, currently there is no cure for this devastating disease.

Breakthrough in nanotechnology could make laboratory tests more sensitive

A laboratory test used to detect disease and perform biological research could be made more than 3 million times more sensitive, according to researchers who combined standard biological tools with a breakthrough in nanotechnology.

2 Jun 2012

End-of-life care in the US can be better

As Americans live longer, more generations are being impacted by advanced illnesses, such as Alzheimer's disease, cancer and heart disease. The nation's healthcare system, specifically Medicare, is being used like never before. Many families are enduring unbearable stress and strained relationships as they try to guess what kind of care their loved one wants. The country needs solutions.

1 Jun 2012

SRI, ChromaDex form collaboration on METLIN database

ChromaDex Corporation, an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, cosmetic and pharmaceutical industries, announced today that it has formed a collaboration with The Scripps Center for Metabolomics to generate tandem mass spectrometry data for compounds from the ChromaDex natural products and phytochemical catalog.

1 Jun 2012

Molecular structure of APP protein could lead to new therapeutics for AD

The molecular structure of a protein involved in Alzheimer's disease - and the surprising discovery that it binds cholesterol - could lead to new therapeutics for the disease, Vanderbilt University investigators report in the June 1 issue of the journal Science.

1 Jun 2012

Innovative model of dementia is now been used to treat over 1,000 patients

An innovative model of dementia care that significantly reduces emergency department visits and hospitalizations, and encourages use of medications that are not harmful to older brains, has now been used to treat over 1,000 patients. The Aging Brain Care model was developed by researcher-clinicians from the Regenstrief Institute and the Indiana University School of Medicine.

1 Jun 2012

Personalized medicine and the Human Genome Project

It’s nearly a decade since the completion of the Human Genome Project, (1) which aimed to sequence the complete human genome.

1 Jun 2012

New method can solve 3-D structures of integral membrane proteins

A new method for rapidly solving the three-dimensional structures of a special group of proteins, known as integral membrane proteins, may speed drug discovery by providing scientists with precise targets for new therapies, according to a paper published May 20 in Nature Methods.

31 May 2012

NYU Langone establishes unique neuromodulation center

The Department of Neurosurgery at NYU Langone Medical Center has established a unique, multidisciplinary neuromodulation center for the treatment of complex neurological conditions including movement disorders like Parkinson's disease, chronic pain and psychiatric condition such as obsessive compulsive disorder and severe depression.

31 May 2012

TSRI receives $2 million donation from Esther B. O'Keeffe Charitable Foundation

The Esther B. O'Keeffe Charitable Foundation has made a $2 million donation to The Scripps Research Institute to fund biomedical research and education on the Florida campus. In recognition of the gift, the Founders Room and the adjoining board room at Scripps Florida have been named the Esther B. O'Keeffe Founders Suite.

31 May 2012

Study shows how tafamidis drug works against amyloid disease

Scientists from The Scripps Research Institute and Pfizer Inc. have published a new study showing how a new drug called tafamidis (Vyndaqel) works.

31 May 2012

Exendin-4 significantly minimizes damage in TBI animal models

Although the death toll is relatively low for people who suffer from traumatic brain injury (TBI), it can have severe, life-long consequences for brain function. TBI can impair a patient's mental abilities, impact memory and behavior, and lead to dramatic personality changes. And long-term medical treatment carries a high economic cost.

30 May 2012

Glia seem to play two opposing roles in protecting nerve cells from damage

A protein produced by the central nervous system's support cells seems to play two opposing roles in protecting nerve cells from damage, an animal study by Johns Hopkins researchers suggests: Decreasing its activity seems to trigger support cells to gear up their protective powers, but increasing its activity appears to be key to actually use those powers to defend cells from harm.

30 May 2012

Neural protein plays two opposing roles

A protein produced by the central nervous system’s support cells seems to play two opposing roles in protecting nerve cells from damage, an animal study by Johns Hopkins researchers suggests: Decreasing its activity seems to trigger support cells to gear up their protective powers, but increasing its activity appears to be key to actually use those powers to defend cells from harm.

29 May 2012

Better education early in life may help protect cognitive abilities

Exposure to solvents at work may be associated with reduced thinking skills later in life for those who have less than a high school education, according to a study published in the May 29, 2012, print issue of Neurology, the medical journal of the American Academy of Neurology.

29 May 2012

EMA CHMP issues positive opinion to Eisai’s Fycompa for treatment of partial-onset seizures

Eisai announced today that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for the use of Fycompa (perampanel) as an adjunctive treatment of partial-onset seizures, with or without secondarily generalised seizures, in patients with epilepsy aged 12 years and older.

29 May 2012

UCSD scientists receive new CIRM grants to conduct stem cell-based research

Five scientists from the University of California, San Diego and its School of Medicine have been awarded almost $12 million in new grants from the California Institute for Regenerative Medicine (CIRM) to conduct stem cell-based research into regenerating spinal cord injuries, repairing gene mutations that cause amyotrophic lateral sclerosis and finding new drugs to treat heart failure and Alzheimer's disease.

28 May 2012